Company Overview

At Akili, we're building an entirely new class of medical products: clinically-validated cognitive therapeutics, assessments, and diagnostics that look and feel like high quality entertainment applications. This new type of Electronic Medicine™ can be deployed remotely directly to the patient, prescribed and tracked by physicians, and developed at a fraction of the cost of traditional medical approaches.

Akili was co-founded by PureTech (a technology development company tackling tomorrow's biggest healthcare challenges), leading cognitive neuroscientists, and top-tier entertainment software creators. Our operational team is a mix of biomedical scientists and experts in medical device commercialization and interactive design.

Operations Team

Matthew Omernick

Matthew Omernick

Executive Creative Director

Mr. Omernick was most recently Executive Art Director at LucasArts, the video game division of Lucasfilm. Mr. Omernick oversaw studio-wide art teams on multiple projects. Managing and directing talented artists and animators, he ensured the overall quality and consistency of the studio's visuals, while developing technology and production plans to deliver quality art, on time and on budget. He had been with LucasArts since July of 2003. Prior to that, he held Senior positions at Microsoft, Dreamworks, Electronic Arts, and Day 1 Studios. Mr. Omernick has shipped over 15 game titles including, Star Wars: The Force Unleashed, Mercenaries, Star Wars: Battlefront, and the critically acclaimed Medal of Honor franchise. He has spent over seven years teaching college-level computer graphics courses at Cal State, The Academy of Art University and the Art Institute of San Francisco. He also authored the book, “Creating the Art of the Game,” published in 2004, which has become an industry and educational standard.

Adam Piper

Adam Piper

Lead Engineer/Designer

Mr. Piper is an interactive entertainment designer/programmer with a decade of games industry experience. He has has worked on several large projects including Star Wars: The Force Unleashed and R&D efforts to bring Industrial Light and Magic feature film technology into real-time games. After receiving a B.S. in Computer Graphics from Purdue University, he began as a Technical Artist at Lucas Arts Entertainment. Shortly thereafter becoming a Programmer for three years, and eventually settling in as a Designer with a talent for building epic and adventurous action experiences. After five years as a designer, He grew to become a multi-disciplinary developer and Creative Director working with a small Lucas prototyping group. The group focused on implementing concepts in the online and emerging platforms space. Mr. Piper has also independently launched a few of his own apps in the smartphone/tablet space. He has a passion for implementation and is looking to bring his skills to forward thinking projects and people.

Eddie Martucci

Eddie Martucci, Ph.D.

Vice President of Research and Development

Dr. Martucci has spent 5 years at PureTech Health, where he is currently a Principal. At PureTech, Dr. Martucci co-founded Akili Interactive Labs and two other health-focused start-ups, and helped launch PureTech's HealthcareIT initiative. He was previously a Kauffman Entrepreneur Fellow, a program sponsored by the Kauffman Foundation of Kansas City, MO. Prior to joining the team at PureTech, Dr. Martucci completed his graduate work at Yale University in the Departments of Pharmacology and Molecular Biophysics & Biochemistry, focusing on structure-based drug design. He led a research project that characterized a potential enzyme drug target and identified two novel chemical scaffolds as potent proof-of-concept compounds for novel therapy. Dr. Martucci received his B.S. in Biochemistry from Providence College, and his M.Phil. and Ph.D. from Yale University.

Eric Elenko

Eric Elenko, Ph.D.

Acting Chief Business Officer, Board Member

Dr. Elenko is a Partner at PureTech Ventures, where he has been a co-founder of 5 life science companies, including 3 focused on the central nervous system. Prior to joining PureTech, Dr. Elenko was a consultant with McKinsey & Company where he advised senior executives of both Fortune 500 and specialty pharmaceutical companies on a range of issues such as product licensing, mergers and acquisitions, R&D strategy, and marketing. Some of his projects at McKinsey included working on a multi-billion dollar merger, crafting a brand strategy for a blockbuster drug, and recommending both pre-clinical and approved products for licensing. Dr. Elenko received his BA in Biology from Swarthmore College and his PhD in Biomedical Sciences from University of California, San Diego.

Scott Kellogg

Scott C. Kellogg

Vice President of Operations

Mr. Kellogg has worked in the medical technology industry for over 22 years and is currently the Vice President of Operations for Akili Interactive Labs and Follica Bio. Prior to joining PureTech Ventures, Mr. Kellogg was an integral member of the founding teams at Afferent, Corp., Sontra Medical, Inc., and UltraCision, Inc., where he served as the Vice President of Business Operations, Vice President of Development, Vice President of R&D, and Director of Engineering, respectively.

In these leadership roles, Mr. Kellogg was focused on commercializing novel medical technology. The technologies included surgical modalities, transdermal analyte detection, point-of-care diagnostics, transdermal drug delivery, neuro-stimulation, and therapeutic drug/device combinations. Additionally, he served in lead project management roles at Mentor Medical, Inc. and Ethicon Endo-Surgery, Inc.

Mr. Kellogg graduated with high honors from the University of Massachusetts at Amherst with a BS in Engineering and received his MS and MBA from Northeastern University. He is an inventor on many domestic and international patents and the lead inventor on the key patents for the Harmonic Scalpel. In 2004 he was awarded Popular Science’s “Best of what’s new in health care.”.

Jeffery Bower

Jeffery Bower, Ph.D.

Director of Data Science and Psychometrics

Jeffrey is a cognitive scientist with expertise in neural-plasticity and computational modeling. Before joining Akili Interactive labs, his previous appointment was at the Department of Cognitive, Linguistic and Psychological Sciences at Brown University. There, he lead research that investigated the neurological correlates of motion processing deficits associated with age using FMRI --- the primary goal being the design of neuro-therapeutic interventions to rehabilitate visual function in the elderly. Throughout his graduate and post-graduate career, Jeffrey's research has focused on quantifying the sources of age-related declines in motion perception through computational modeling. Through his experimental and theoretical research, Jeffrey has gained extensive experience modeling cognitive processes and advanced knowledge of statistics, computational models, Monte Carlo simulations, psychophysics, psychometrics, and machine-learning techniques. Jeffrey earned his Ph.D. from the University of California Riverside in cognitive psychology with an emphasis on visual cognition.

Founding Advisors & Board Members

Adam Gazzaley
Daphne Bavelier
Ben Shapiro
Daphne Zohar
Philip Rosedale
Adam Gazzaley

Adam Gazzaley, M.D./Ph.D.

Chief Science Advisor, Co-Founding Advisor

Dr. Gazzaley is the founding director of the Neuroscience Imaging Center at the University of California, San Francisco, an Associate Professor in Neurology, Physiology and Psychiatry, and Principal Investigator of a cognitiveneuroscience laboratory. His laboratory studies neural mechanisms of perception, attention and memory, with an emphasis on the impact of distraction and multitasking on these abilities. His unique research approach utilizes a powerful combination of human neurophysiological tools, including functional magnetic resonance imaging (fMRI), electroencephalography (EEG) and transcranial magnetic stimulation (TMS)). A major accomplishment of his research has been to expand our understanding of alterations in the aging brain that lead to cognitive decline. His most recent studies explore how we may enhance our cognitive abilities, and/or prevent them from declining in various neuropsychiatric conditions, and he is a pre-eminent thought-leader on the use of interactive environments (including video games) to achieve cognitive enhancement. He has authored over 70 scientific articles, delivered over 250 invited presentations around the world, and his research and perspectives have been consistently profiled in high-impact media, such as The New York Times, Wall Street Journal, TIME, CNN, PBS, NPR, and NBC Nightly News. Recently, he wrote and hosted the nationally televised, PBS-sponsored special “The Distracted Mind with Dr. Adam Gazzaley”.

Daphne Bavelier

Daphne Bavelier, Ph.D.

Co-Founding Advisor

Dr. Bavelier is a Professor of Cognitive Neuroscience at the University of Geneva, Switzerland, and of Brain and Cognitive Sciences at the University of Rochester, NY, USA. She is a Biology graduate from the ‘Ecole Normale Superieure de Paris’, France, received a PhD in Brain and Cognitive Sciences from the Massachusetts Institute of Technology, Boston, MA and trained in human brain plasticity at the Salk Institute, San Diego CA. Her research combines behavioral and brain imaging approaches to study how humans learn and how the brain adapts to changes in experience, either by nature - for example, deafness - or by training - for example, playing video games. Recently, her laboratory demonstrated that playing certain types of entertainment video games induces a vast array of improvements that extends well beyond the specifics of video game play. Based on these findings, her lab now utilizes an array of converging methods to identify the factors that underlie brain plasticity and generalization of learning after video game play as well as attempt to harness the knowledge for practical purposes. Her scientific contributions have been recognized by several awards including a John Merck Scholar Awards, a 21st Century Award by The James S. McDonnell Foundation, and a finalist prize in the Blavatnik Awards for Young Scientists in 2008. Her work has been featured in many outlets nationally and internationally, including the New York Times, CNN, the Washington Post, the Economist. BBC, and recently in a TED talk.

Ben Shapiro

Bennett Shapiro, M.D.

Board Member

Dr. Shapiro is a Senior Partner and Chairman of the Board of PureTech Ventures. Formerly he was Executive Vice President in charge of Worldwide Basic, Preclinical, Licensing and External Research for Merck, where he was responsible for programs that resulted in FDA registration of approximately 25 drugs and vaccines. Previously, he was Professor and Chairman of the Department of Biochemistry at the University of Washington. He is the author of over 120 papers on the molecular regulation of cellular behavior and the biochemical events that integrate the cascade of cellular activities at fertilization. He has been a Board member of a number of life science companies, including VBL, Celera, Momenta, Elixir, Satori, and Ikaria, as well as serving on the Board of Drugs for Neglected Disease Initiative.

Daphne Zohar

Daphne Zohar

Board Member

Daphne Zohar is the founder and managing partner of PureTech, a technology development company tackling tomorrow’s biggest healthcare challenges. Ms. Zohar was recognized by Fierce Biotech as one of the “Top 10 Women in Biotech,” BioWorld as one of 28 leaders predicted to be the “movers and shakers” of the biotechnology industry over the next twenty years, and by the Boston Globe as one of the “Top 15 Innovators.” A successful entrepreneur, Ms. Zohar created PureTech and assembled a leading team to help implement her vision for the firm. She sits on the Boards of Directors of PureTech, Enlight (a cross disciplinary consortium of leading healthcare and pharma companies), Follica Inc., Akili Interactive Labs, Vedanta Bioscience, Mandara Sciences, Karuna Pharmaceuticals, and Tal Medical. She also sits on the Technology Development Fund Advisory Board at Children’s Hospital Boston and is an Editorial Advisor to Xconomy, a national technology news blog.

Philip Rosedale

Philip Rosedale

Board Member

In 1995, Philip Rosedale created an innovative Internet video conferencing product (called "FreeVue"), which was later acquired by RealNetworks where (in 1996) he went on to become Vice President and CTO. In 1999, Rosedale left RealNetworks, founded Linden Lab and built a virtual civilization called Second Life, fulfilling his lifelong dream of creating an open-ended, Internet-connected virtual world. Since leaving Second Life, Rosedale has worked on several experiments in distributed work and computing, including Coffee & Power and In 2013, he co-founded High Fidelity Inc. to explore the future of a next-generation virtual reality system.

Scientific Approach

Akili functions on the premise that the advances in neuroscience research and consumer-facing technology development are enabling a new way to sensitively measure neural function wherever the patient may be. And that precisely measuring and monitoring specific deficits provides an opportunity for remote therapeutic intervention. Akili's products address these in a variety of patient populations.

The science behind our first platform, "Project: EVO", was developed at the University of California, San Francisco by Dr. Adam Gazzaley, Founding Director of the UCSF Neuroscience Imaging Center and Akili's Chief Science Advisor. Dr. Gazzaley's research has led to a patent-pending new software-based method to measure and improve a key system of executive function known as "interference processing." We've deployed these mechanics in a highly-engaging videogame-like environment that runs on mobile phones and tablets, and meets all requirements for rigorous clinical studies. The Project: EVO platform is currently being tested in a variety of clinical studies in multiple patient populations around the globe.


Akili works with top universities and premier partners in the healthcare space to bring our products to market.

Additionally, Akili is in the process of licensing and accelerating product development of the very newest published and as-yet-unpublished neuroscience findings that could address major medical indications. If you have a research program on a patient population with cognitive deficits, or new science that you would like to develop into engaging medical products, please contact Akili at

Akili News

Akili's novel healthcare approach and the technology behind our first product platform has been covered extensively in recent popular and industry-specific media outlets. Stay tuned for more updates!


If you are interested in partnering or collaborating with Akili to test our technology in a specific patient or healthy population, please email us at We have offices in Boston and San Francisco, the epicenters for development in both biotech and interactive design. And we’re hiring!

500 Boylston Street

Suite 1600

Boston, MA 02116